Applied Therapeutics EBIT

The latest EBIT for APLT is $-100M as of September 2025. That compares with $-75M in the prior-year period — down 33.4% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Applied Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, APLT's EBIT moved from $-75M to $-100M — a 33.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Applied Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, APLT currently prints $-100M for EBIT, while the sector average sits near $22B. That is roughly 100.4% below the sector mean. Large gaps often invite a closer look at Applied Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-100M for APLT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting APLT's EBIT ($-100M), review year-over-year change from $-75M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.